Search results for "Insulin"

showing 10 items of 1360 documents

Exercise, the endocannabinoid system and metabolic health

2013

As obesity and associated metabolic disorders, such as type 2 diabetes and dyslipidemia, are becoming one of the most serious health problems worldwide, development of effective therapies is a high priority. In the search for treatments, the recently discovered endocannabinoid system (ECS) has begun to garner attention, and a wealth of research is now focusing on this unique neuromodulatory system named after the plant that led to its discovery. The ECS consists of G protein-coupled cannabinoid receptors (CB1 and CB2), their endogenous lipid-derived ligands (endocannabinoids, N-arachidonoylethanolamine, named anandamide (AEA) and 2-arachidonoylglycerol (2-AG)) and the enzymes for ligand syn…

medicine.medical_specialtyCannabinoid receptorbusiness.industryCalorie restrictionAdipose tissuePhysical Therapy Sports Therapy and RehabilitationType 2 diabetesmedicine.diseaseEndocannabinoid systemInsulin resistanceEndocrinologyInternal medicinemedicinelipids (amino acids peptides and proteins)Orthopedics and Sports MedicineReceptorbusinessDyslipidemiaJournal of Sport and Health Science
researchProduct

Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.

1998

Angiotension converting enzyme (ACE) inhibitors and beta-blockers have been reported to possess disparate effects on insulin sensitivity. The aim of this study was to study the effects of the selective beta-1 blocker bisoprolol and of the ACE inhibitor captopril on cellular insulin action in hypertensive individuals. After washout, 12 mild to moderate essential hypertensives were randomized in a double-blind manner to 5 mg bisoprolol daily or 25 mg captopril twice daily for 8 weeks. Erythrocyte insulin binding and insulin-stimulated tyrosine kinase (TK) activity were measured before and after therapy. Both agents decreased diastolic blood pressure significantly (bisoprolol 96.5+/-0.9 to 87.…

medicine.medical_specialtyCaptoprilmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsEssential hypertensionInsulin resistanceDouble-Blind MethodInternal medicineInternal MedicinemedicineBisoprololHumansAgedbiologybusiness.industryInsulinCaptoprilAngiotensin-converting enzymeMiddle Agedmedicine.diseaseReceptor InsulinInsulin receptorEndocrinologyBisoprololACE inhibitorHypertensionbiology.proteinInsulin Resistancebusinessmedicine.drugAmerican journal of hypertension
researchProduct

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Genistein in the Metabolic Syndrome: Results of a Randomized Clinical Trial

2013

Context: This study was performed to evaluate the effects of genistein on metabolic and cardiovascular risk factors in Caucasian postmenopausal subjects with metabolic syndrome (MetS). Objective: Our objective was to assess the effects of genistein on surrogate endpoints associated with diabetes and cardiovascular disease. Design and Setting: This was a randomized, double-blind, placebo-controlled trial at 3 university medical centers in Italy. Patients: Patients included 120 postmenopausal women with MetS according to modified Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Tre…

medicine.medical_specialtyCardiovascular Risk Factorsgenistein aglycone; metabolic syndrome; Cardiovascular Risk FactorsEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)PlaceboBiochemistrylaw.inventionEndocrinologyInsulin resistanceDouble-Blind MethodRandomized controlled triallawDiabetes mellitusInternal medicinemedicineHumansgenistein aglyconeNational Cholesterol Education ProgramAgedMetabolic SyndromeSurrogate endpointbusiness.industryMetabolic Syndrome XCholesterol HDLBiochemistry (medical)Cholesterol LDLMiddle Agedmedicine.diseaseGenisteinEndocrinologyFemaleInsulin ResistanceMetabolic syndromebusinessHumanThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Glucose Metabolism in Children With Growth Hormone Deficiency

2018

Background: The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis has a fundamental impact on glucose metabolism. Therefore, both untreated GH deficiency (GHD) and GH treatment (GHT) may be associated with some metabolic alterations, although the abnormalities of glucose metabolism have been investigated by relatively few studies as main outcomes. Aim: The present review summarizes the available data on glucose metabolism in children with GHD, providing an overview of the current state of the art in order better to clarify the real metabolic impact of GHD and GHT. Methods: Among all the existing studies, we evaluated all original studies that fulfilled our criteria for analysis …

medicine.medical_specialtyChildren; Glucose; Growth hormone; Insulin sensitivity; Metabolism; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismMini Review030209 endocrinology & metabolismCarbohydrate metabolismGrowth hormonelcsh:Diseases of the endocrine glands. Clinical endocrinologyReporting parametersGrowth hormone deficiencySettore MED/13 - EndocrinologiaFasting glucose03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologychildrenInternal medicinemedicineGlucose homeostasisinsulin sensitivityglucoselcsh:RC648-665business.industryMetabolismmedicine.diseaseEndocrinology030220 oncology & carcinogenesisgrowth hormonebusinessmetabolismFrontiers in Endocrinology
researchProduct

Familial Combined Hyperlipidemia, Metabolic Syndrome and Cardiovascular Disease

2006

Our aim was to investigate the relationship between metabolic syndrome and cardiovascular disease (i.e., survivors of myocardial infarction) in patients with familial combined hyperlipidemia (FCH). We compared a group of 20 male patients with FCH who had survived a myocardial infarction with two other groups matched for age and body mass index, comprising 20 individuals with FCH who had not had a myocardial infraction and 20 control subjects. Plasma lipid, glucose, and insulin levels were determined. Metabolic syndrome was judged to present on the basis of World Health Organization (WHO) and National Cholesterol Education Program-Adult treatment panel (NCEP-ATPIII) criteria. Differences bet…

medicine.medical_specialtyCholesterolbusiness.industryInsulinmedicine.medical_treatmentGeneral MedicineDiseasemedicine.diseaseLogistic regressionchemistry.chemical_compoundInsulin resistancechemistryInternal medicinemedicineCardiologyMyocardial infarctionMetabolic syndromebusinessBody mass indexRevista Española de Cardiología (English Edition)
researchProduct

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

2020

The rising prevalence of the metabolic syndrome has led to an increase of non-alcoholic fatty liver disease (NAFLD), and its progressive-inflammatory form called non-alcoholic steatohepatitis (NASH). In recent years, NAFLD and NASH have become major risk factors for developing liver cirrhosis and hepatocellular carcinoma (HCC). In this case, we report a 46-year-old patient with type 2 diabetes mellitus and metabolic comorbidities including obesity and arterial hypertension, who was referred because of rising liver enzymes. After clinical and diagnostic evaluation, the patient was diagnosed with NASH-associated liver cirrhosis, Child-Pugh stage B. A normal blood sugar level was difficult to …

medicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityLiver transplantationChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineFatal OutcomeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineObesityMetabolic Syndromebusiness.industryFatty liverLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesDiabetes Mellitus Type 2Hepatocellular carcinomaHypertension030211 gastroenterology & hepatologyMetabolic syndromeSteatohepatitisInsulin ResistancebusinessZeitschrift fur Gastroenterologie
researchProduct

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

2013

Non-alcoholic fatty liver disease (NAFLD) refers to a disease spectrum, ranging from mere hepatic steatosis to hepatic necroinflammation (NASH, non-alcoholic steatohepatitis). NASH often leads to fibrosis, which can progress to cirrhosis with a high risk of liver failure and hepatocellular carcinoma. The course of NAFLD is highly variable, and only a minority of patients (2-3%) progress to end-stage liver disease. However, due to a dramatic increase of the risk factors for NAFLD, that is obesity and insulin resistance/type 2 diabetes, that affect 15-30% and 7-15% of subjects, in most industrialized countries, respectively, NAFLD has become the most frequent liver disease and is even conside…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesmedicine.diseaseBioinformaticsdigestive systemdigestive system diseasesLiver diseaseEndocrinologyInsulin resistanceLipotoxicityInternal medicinemedicineSteatosisSteatohepatitisMetabolic syndromebusinessJournal of Gastroenterology and Hepatology
researchProduct

Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management

2020

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismPneumonia ViralType 2 diabetesDiabetes ComplicationsDisease susceptibilityInsulin resistanceDiabetes mellitusPandemicmedicineInternal MedicineDiabetes MellitusHumansEndothelial dysfunctionIntensive care medicinePandemicsbusiness.industryCOVID-19medicine.diseaseObesityCommentarycardiovascular disease endothelial dysfunction insulin resistance obesity type 2 diabetes COVID-19 Coronavirus Infections Diabetes Complications Diabetes Mellitus Disease Susceptibility Humans Pandemics Pneumonia ViralDisease SusceptibilitybusinessCoronavirus Infections
researchProduct

Effect of insulin and insulin-resistance on the glomerular filtration rate and microalbuminuria in hypertensive patients

2001

medicine.medical_specialtyCreatininebusiness.industryInsulinmedicine.medical_treatmentRenal functionRadioimmunoassaymedicine.diseasechemistry.chemical_compoundInsulin resistanceEndocrinologyBlood pressurechemistryInternal medicineDiabetes mellitusInternal MedicineMedicineMicroalbuminuriabusinessAmerican Journal of Hypertension
researchProduct